Introduction
============

Positron emission tomography (PET) is a molecular imaging technique that requires molecules labelled with a positron-emitting radionuclide. Fluorine-18 is a widely used positron emitting radionuclide in part due to its favourable decay properties, and the numerous clinical applications of 2-deoxy-2-\[^18^F\]fluoro-[d]{.smallcaps}-glucose, a radiopharmaceutical prepared from \[^18^F\]fluoride.[@cit1] While radiochemists have in recent years focused their efforts on methods enabling ^18^F-fluorination[@cit2] and ^18^F-trifluoromethylation of (hetero)arenes,[@cit2],[@cit3] ^18^F-difluoromethylation reactions have been less studied despite the importance of the CF~2~H motif[@cit4] in radioligand design for drug discovery programmes. In 2013, we reported a Ag([i]{.smallcaps})-mediated ^18^F-fluorodecarboxylation of 2-fluoro-2-arylacetic acids with \[^18^F\]Selectfluor (bis)triflate leading to \[^18^F\]ArCF~2~H.[@cit5] Subsequently, we disclosed a Ag([i]{.smallcaps})-mediated halogen exchange reaction using \[^18^F\]fluoride.[@cit6] In 2016, a multi-step method to label \[^18^F\]ArCF~2~H from aryl (pseudo)halides was disclosed by Ritter and co-workers.[@cit7] Later, Liang and co-workers demonstrated that halogen exchange of benzyl (pseudo)halides with \[^18^F\]fluoride followed by oxidative benzylic C--H fluorination with Selectfluor afforded \[^18^F\]ArCF~2~H with improved molar activity.[@cit8] Despite these advances, ^18^F-difluoromethylation remains a challenging problem, especially for structurally complex targets. We initially considered adapting difluoromethylation reactions operating *via* C--H functionalisation.[@cit9] Whilst this strategy is ideal for (hetero)arenes with innate reactivity leading to site-selective ^18^F-difluoro-methylation, substrates that are not reactive or too reactive would be unsuitable, thereby limiting applicability for radioligand synthesis. We therefore opted to develop a method using pre-functionalised aryl boron reagents; these are amenable to ^18^F-fluorination and ^18^F-trifluoromethylation,[@cit10] so extension to ^18^F-difluoromethylation was viewed as a valuable development. Building on our Ag([i]{.smallcaps})-mediated ^18^F-fluorodecarboxylation towards \[^18^F\]ArCF~2~H,[@cit5] a reaction requiring \[^18^F\]Selectfluor (bis)triflate ([Scheme 1A](#sch1){ref-type="fig"}),[@cit11] and on the Mn-mediated fluorodecarboxylation reported by Groves and co-workers, a reaction using \[^18^F\]fluoride ([Scheme 1B](#sch1){ref-type="fig"}),[@cit12],[@cit13] we envisaged that the ^18^F-fluorodecarboxylation of 2-fluoro-2-arylacetic acids with \[^18^F\]fluoride could afford \[^18^F\]ArCF~2~H. The beneficial effect of fluorine substitution on radical stabilisation would be favorable for this process.[@cit5],[@cit14] This approach would require a robust method to cross-couple the aryl boron reagent with ethyl bromofluoroacetate followed by hydrolysis to access the carboxylic acid precursor; we gave preference to a coupling methodology applying Cu-catalysis instead of Pd or Ni, a decision driven by guidelines for residual metals in (radio)pharmaceuticals.[@cit15] The proposed strategy therefore relies on three readily available components, the boron reagent, ethyl bromofluoroacetate, and \[^18^F\]fluoride ([Scheme 1C](#sch1){ref-type="fig"}).[@cit16]

![(A) Ag([i]{.smallcaps})-mediated ^18^F-fluorodecarboxylation with \[^18^F\]Selectfluor (bis)triflate. (B) Mn([iii]{.smallcaps})-mediated ^18^F-fluorodecarboxylation with \[^18^F\]fluoride towards \[^18^F\]ArCH~2~F. (C) Synthetic plan towards \[^18^F\]ArCF~2~H from boron reagents and \[^18^F\]fluoride.](c8sc05096a-s1){#sch1}

Results and discussion
======================

Preliminary experiments demonstrated that the model fluoro-substituted carboxylic acid **1a** is amenable to fluorodecarboxylation with fluoride. When an equimolar mixture of **1a** and **2a** was treated with Mn(tmp)Cl (2.5 mol%), Et~3~N·3HF (1.2 equiv.) and PhIO (3.3 equiv.) in MeCN at 50 °C, **3a** and **4a** were obtained in 44% and 20% yield, respectively. This result indicates that the fluorine-substituted precursor **1a** is more reactive than non-fluorinated **2a** towards fluorodecarboxylation ([Scheme 2A](#sch2){ref-type="fig"}). We verified that product **4a** did not undergo fluorination *via* C--H functionalisation under these conditions.[@cit17] When an excess of **1a** (1 equiv.) was treated with TBAF (0.1 equiv.), PhIO (0.5 equiv.) and Mn(tmp)Cl (0.2 equiv.) in MeCN, **3a** was obtained in 50% yield (determined by ^19^F NMR based on TBAF consumption) ([Scheme 2B](#sch2){ref-type="fig"}). Notably, quantitative fluoride incorporation was observed applying similar reaction conditions to the preformed hypervalent iodine complex **5a** ([Scheme 2C](#sch2){ref-type="fig"}). These preliminary data boded well for ^18^F-labeling with \[^18^F\]fluoride as the limiting reagent, and prompted the development of a robust protocol to convert aryl boron reagents into 2-fluoro-2-arylacetic acids.

![(A) Competition studies evaluating the effect of fluorine substitution on fluorodecarboxylation. (B) Reaction with sub-stoichiometric fluoride. (C) Reaction of iodine([iii]{.smallcaps}) complex **5a** with sub-stoichiometric fluoride. Yields of isolated products. Mn(tmp)Cl = Mn([iii]{.smallcaps}) *meso*-tetra(2,4,6-trimethylphenyl)porphyrin chloride. ^a^Yield determined by ^19^F NMR using α,α,α-trifluorotoluene as internal standard.](c8sc05096a-s2){#sch2}

The cross-coupling of arylboronic acids and ethyl bromofluoroacetate has been reported using an excess of boron reagent under Ni or Pd catalysis, but has not been accomplished under Cu catalysis.[@cit18]--[@cit22] Initial studies reacting \[1,1′-biphenyl\]-4-ylboronic acid **6a** (2 equiv.) with ethyl bromofluoroacetate (1 equiv.) in the presence of 1,10-phenanthroline (**L1**, 20 mol%), CuI (20 mol%) and Cs~2~CO~3~ (2 equiv.) in dioxane (0.2 M) under N~2~ at 100 °C afforded **7a** in 7% yield ([Table 1](#tab1){ref-type="table"}, entry 1). When 2,2′:6′,2′′-terpyridine (**L2**) was used as the ligand, the yield was significantly improved to 58% yield ([Table 1](#tab1){ref-type="table"}, entry 2). When the stoichiometry was altered to 1 equivalent of **6a** and 2 equivalents of ethyl bromofluoroacetate in the presence of 4,4′,4′′-tri-*tert*-butyl-2,2′:6′,2′′-terpyridine (**L3**) in toluene instead of dioxane **7a** was obtained in 63% yield ([Table 1](#tab1){ref-type="table"}, entry 3). Further optimisation increasing the concentration led to the optimal protocol consisting of treating **6a** (0.1 mmol) with ethyl bromofluoroacetate (0.2 mmol), Cs~2~CO~3~ (0.2 mmol), CuI (20 mol%) and **L3** (20 mol%) in toluene (0.4 M) at 100 °C. Under these reaction conditions, **7a** was isolated in 82% yield ([Table 1](#tab1){ref-type="table"}, entry 4). A one-pot sequence involving cross-coupling followed by hydrolysis with MeOH and aqueous K~2~CO~3~ afforded **8a** isolated in 75% yield ([Table 1](#tab1){ref-type="table"}, entry 5). In the absence of ligand and/or copper source ([Table 1](#tab1){ref-type="table"}, entries 6, 7), no product formation was observed. Furthermore, no reaction was observed with CuCl~2~ ([Table 1](#tab1){ref-type="table"}, entry 8), or when the reaction solvent was DMF or DMSO ([Table 1](#tab1){ref-type="table"}, entry 9).

###### Optimisation of the Cu-catalysed cross-coupling of aryl boronic acid **6a** with ethyl bromofluoroacetate towards ester **7a** and the corresponding carboxylic acid **8a**[^*a*^](#tab1fna){ref-type="fn"}

  ![](c8sc05096a-u1.jpg){#ugr1}                                                               
  ----------------------------------------- --------------------- --------- -------- -------- -------------------------------------------------------------------------------------
  1[^*c*^](#tab1fnc){ref-type="table-fn"}   Dioxane (0.2 M)       CuI       **L1**   **7a**   7%
  2[^*c*^](#tab1fnc){ref-type="table-fn"}   Dioxane (0.2 M)       CuI       **L2**   **7a**   58%
  3                                         Toluene (0.2 M)       CuI       **L3**   **7a**   63%
  4[^*d*^](#tab1fnd){ref-type="table-fn"}   Toluene (0.4 M)       CuI       **L3**   **7a**   82%[^*e*^](#tab1fne){ref-type="table-fn"}
  5[^*d*^](#tab1fnd){ref-type="table-fn"}   Toluene (0.4 M)       CuI       **L3**   **8a**   75%[^*e*^](#tab1fne){ref-type="table-fn"} ^,^[^*f*^](#tab1fnf){ref-type="table-fn"}
  6[^*d*^](#tab1fnd){ref-type="table-fn"}   Toluene (0.4 M)       CuI       ---      **7a**   0%
  7[^*d*^](#tab1fnd){ref-type="table-fn"}   Toluene (0.4 M)       ---       ---      **7a**   0%
  8[^*d*^](#tab1fnd){ref-type="table-fn"}   Toluene (0.4 M)       CuCl~2~   **L2**   **7a**   0%
  9[^*d*^](#tab1fnd){ref-type="table-fn"}   DMF or DMSO (0.2 M)   CuI       **L3**   **7a**   0%

^*a*^Screening reactions performed on 0.1 mmol scale.

^*b*^Yield determined by ^19^F-NMR using α,α,α-trifluorotoluene as internal standard.

^*c*^2 equiv. of **6a** and 1 equiv. of ethyl bromofluoroacetate.

^*d*^1 equiv. of **6a**, and 2 equiv. of ethyl bromofluoroacetate.

^*e*^Yield of isolated product.

^*f*^One-pot procedure towards **8a**.

These optimised conditions gave access to a range of 2-fluoro-2-arylacetic acids ([Scheme 3](#sch3){ref-type="fig"}). The reaction is broad in scope and tolerates various functional groups, for example alkyl **8c--8e** and **8s--8u**, alkoxy **8f**, **8g**, trifluoromethyl **8h**, bromo **8p**, **8q**, iodo **8r**, and aldehyde **8i** all performed well. Substrates featuring heterocycles such as dibenzofuran **8j**, pyridine **8k**, triazole **8l**, and pyrazoles **8m**, **8n** are also suitable coupling partners applying our optimised protocol affording the desired products in 40% to 70% yield. Additionally, this cross-coupling chemistry afforded **8o**, a derivative of fenofibrate, in 72% yield. Finally, the reaction was amenable to scale-up to 5 mmol ([Scheme 3](#sch3){ref-type="fig"}, **8m**).

![Scope of Cu-catalysed cross-coupling. The reactions were performed on a 0.3 mmol scale. Conditions: CuI (20 mol%), **L3** (20 mol%), aryl boronic acid (1 equiv.), ethyl bromofluoroacetate (2 equiv.), Cs~2~CO~3~ (2 equiv.), toluene (0.4 M) at 100 °C for 18 h then one-pot hydrolysis with K~2~CO~3~ (10 equiv.), MeOH/H~2~O (1 : 1), 5 h. ^a^Hydrolysis performed as a subsequent step with K~2~CO~3~ (5 equiv.). ^b^Reaction run on 5 mmol scale. All yields are of isolated products.](c8sc05096a-s3){#sch3}

The key ^18^F-fluorodecarboxylation step was studied next ([Table 2](#tab2){ref-type="table"}). We started our investigation applying protocol A that consists of reacting in one-pot **8b** (0.11 mmol) with PhIO (0.33 mmol), Mn(tmp)Cl (2 mg) and \[^18^F\]TEAF (20--30 MBq) in MeCN (600 μL) at 50 °C; this protocol led to only traces of **\[^18^F\]3b** ([Table 2](#tab2){ref-type="table"}, entry 1). When the loading of PhIO (0.02 mmol) and MeCN (300 μL) was reduced, **\[^18^F\]3b** was obtained in 6% ± 1% radiochemical conversion (RCC) ([Table 2](#tab2){ref-type="table"}, entry 2). Similar results were obtained in DMF ([Table 2](#tab2){ref-type="table"}, entry 3). Reducing the stoichiometry of **8b** led to a significant increase in RCC (22% ± 7%) ([Table 2](#tab2){ref-type="table"}, entry 4). When applying protocol B which consists of mixing **8b** with PhIO, a process generating complex **5b**, prior to the addition of Mn(tmp)Cl (2 mg) and \[^18^F\]TEAF (20--30 MBq) and DMF (300 μL), a drastic improvement was observed, and **\[^18^F\]3b** was obtained in 40% ± 10% RCC (*n* = 10) ([Table 2](#tab2){ref-type="table"}, entry 5). When the reaction was run at 100 °C, the formation of **\[^18^F\]3b** was not observed ([Table 2](#tab2){ref-type="table"}, entry 6). No ^18^F-labelled product was obtained when Mn(tmp)OTs was used as catalyst, or in the absence of Mn(tmp)Cl ([Table 2](#tab2){ref-type="table"}, entries 7 and 8).

###### Optimisation studies for the \[^18^F\]fluorodecarboxylation of **8b**

  ![](c8sc05096a-u2.jpg){#ugr2}                                                                                                                                          
  ------------------------------- -------------------- ------- ----------------------------------------------------------------------------------------------- --------- ------------------------------------------------------
  1                               **8b** (0.11)        A       MeCN[^*c*^](#tab2fnc){ref-type="table-fn"}                                                      0.33      3% ± 1%
  2                               **8b** (0.11)        A       MeCN[^*d*^](#tab2fnd){ref-type="table-fn"}                                                      0.02      6% ± 1%
  3                               **8b** (0.11)        A       DMF[^*d*^](#tab2fnd){ref-type="table-fn"}                                                       0.02      7% ± 2%
  4                               **8b** (0.055)       A       DMF[^*d*^](#tab2fnd){ref-type="table-fn"} ^,^[^*e*^](#tab2fne){ref-type="table-fn"}             0.02      22% ± 7%
  **5**                           **5b** **(0.014)**   **B**   **DMF** [^*d*^](#tab2fnd){ref-type="table-fn"} ^**,**^ [^*e*^](#tab2fne){ref-type="table-fn"}   **---**   **40% ± 10%** [^*f*^](#tab2fnf){ref-type="table-fn"}
  6                               **5b** (0.014)       B       DMF[^*d*^](#tab2fnd){ref-type="table-fn"} ^,^[^*e*^](#tab2fne){ref-type="table-fn"}             ---       0% ± 0%[^*g*^](#tab2fng){ref-type="table-fn"}
  7                               **8b** (0.014)       A       MeCN[^*d*^](#tab2fnd){ref-type="table-fn"}                                                      0.02      0% ± 0%[^*h*^](#tab2fnh){ref-type="table-fn"}
  8                               **5b** (0.014)       B       DMF[^*d*^](#tab2fnd){ref-type="table-fn"} ^,^[^*e*^](#tab2fne){ref-type="table-fn"}             ---       0% ± 0%[^*i*^](#tab2fni){ref-type="table-fn"}

^*a*^Radiochemical conversion.

^*b*^ *n* = number of reactions.

^*c*^600 μL of MeCN.

^*d*^300 μL of MeCN.

^*e*^MeCN removed at 100 °C after dispensing \[^18^F\]TEAF.

^*f*^(*n* = 10).

^*g*^Reaction temperature = 100 °C.

^*h*^Catalyst is Mn(tmp)OTs.

^*i*^No Mn Catalyst.

The fluorine substituent is advantageous for ^18^F-fluorodecarboxylation as demonstrated with a competition experiment subjecting equimolar amount of pre-formed hypervalent iodine([iii]{.smallcaps}) complexes **9a** and **5a** to ^18^F-fluorination with \[^18^F\]TEAF, Mn(tmp)Cl at 50 °C in DMF. Difluoromethylarene **\[^18^F\]3a** was the only product observed in the crude reaction mixture ([Scheme 4A](#sch4){ref-type="fig"}). Furthermore, an additional competition experiment showed that the iodine([iii]{.smallcaps}) complex **5a** is formed preferentially to **9a** ([Scheme 4B](#sch4){ref-type="fig"}). Fluorine substitution therefore facilitates the two steps of the process leading to fluorodecarboxylation.

![(A) Competition experiment subjecting equimolar amount of **9a** and **5a** to \[^18^F\]fluorodecarboxylation. (B) Competition experiment reacting equimolar amount of **1a** and **3a** with PIDA.](c8sc05096a-s4){#sch4}

Protocol B was applied to a selection of arenes using 20--30 MBq of \[^18^F\]fluoride ([Scheme 5](#sch5){ref-type="fig"}). Ether, alkyl, aldehyde, ketone, pyridine, triazole, pyrazole, dibenzofuran motifs were all tolerated. The highest RCCs were obtained for electron rich arenes. **\[^18^F\]3o** derived from a boronic acid analogue of fenofibrate was successfully labelled in 23% ± 4% (*n* = 4). The boronic acid derivative of the COX-II inhibitor ZA140 **6z** was transformed into the labelled difluoromethylated product **\[^18^F\]3z** in 15% ± 2% RCC (*n* = 3).

![Scope of \[^18^F\]fluorodecarboxylation applying protocol B: ^a^ArCHFCO~2~H (0.028 mmol), PhIO (0.5 equiv.), MeCN (1 mL), 50 °C, 10 min then addition of \[^18^F\]TEAF (20--30 MBq) Mn(tmp)Cl (2 mg), DMF (300 μL), 50 °C, 20 min. ^b^ArCHFCO~2~H (0.014 mmol), PhIO (0.5 equiv.), MeCN (1 mL), 50 °C, 10 min then addition of \[^18^F\]Mn(tmp)F (841 MBq) DCE (300 μL), 60 °C, 20 min.](c8sc05096a-s5){#sch5}

The ^18^F-fluorodecarboxylation of **5b** performed with 841 MBq of \[^18^F\]fluoride required further optimisation. For this experiment, \[^18^F\]fluoride was captured on an anion exchange cartridge then eluted using a solution of Mn(tmp)Cl in methanol, resulting in 85% ^18^F-recovery. Lowering the starting material stoichiometry to 0.007 mmol of **5b** and changing the solvent from DMF to DCE afforded the cartridge-purified **\[^18^F\]3b** in a decay corrected RCY of 12% and a molar activity of 3.0 GBq μmol^--1^ in a total synthesis time of 30 minutes.[@cit23]

Pleasingly, ^18^F-fluorodecarboxylation also enabled access to the \[^18^F\]ArOCF~2~H motif. The only known route to label this motif was reported by our group, and required a multi-step synthesis of the ArOCHFCl precursors which were themselves prepared from ArOCHFCO~2~H.[@cit24] The reaction of estrone (1.0 equiv.) with ethyl bromofluoroacetate (1.5 equiv.) and K~2~CO~3~ (2.5 equiv.) in DMF (2 mL) at room temperature followed by a subsequent hydrolysis with aqueous NaOH (2.5 equiv.) in 1 : 1 H~2~O/Et~2~O afforded the precursor required for fluorodecarboxylation. ^18^F-labelling applying protocol B afforded **\[^18^F\]11a** in 21% ± 6% RCC (*n* = 3).

Conclusions
===========

In summary, a novel method was developed to transform aryl boronic acids to \[^18^F\]ArCF~2~H. Prior to labelling, the cross-coupling with ethyl bromofluoroacetate was accomplished under Cu catalysis followed by *in situ* hydrolysis. The radioisotope ^18^F is then introduced in the last step applying a Mn-mediated fluorodecarboxylation with readily available \[^18^F\]fluoride. This study has unveiled three key features for this last transformation. Firstly, the fluorine substituent on the carboxylic acid precursor is advantageous for fluorodecarboxylation; secondly, the benefit of preforming the hypervalent iodine complex prior to ^18^F-fluorination; and thirdly, we have established that Mn-mediated fluorodecarboxylation enables access to \[^18^F\]ArOCF~2~H in addition to \[^18^F\]ArCF~2~H.
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